Most of the Russians have heard about Dubai, but very few are aware of Bahrai...
Johnson & Johnson: it is necessary to wait for the signal
A player of a huge scale, a structure of more than 250 subsidiaries, a vertically integrated holding consisting of the production of sanitary and hygienic goods, medicines, as well as medical and social equipment. This is Johnson & Johnson. The business earns from sales in the consumer segment of the market (17%), in the pharmaceutical (51%) and medical devices sector (32%).
The company has relied on a diversified business model, which allows it to maintain stability in almost any market scenario.
Johnson & Johnson has presented its quarterly report. Its strengths:
There are weak spots – for example, a 1% reduction in sales of medical equipment by the sector in the second quarter to $6.9 billion. In addition, it is worth paying attention to the company’s reduction in expectations for adjusted net profit for 2022 to $10 per share, revenue to $93.3-94.3 billion.
However, in general, the main reporting indicators came out better than forecasts, which allows us to maintain a positive outlook on the prospects of the company’s shares.
The consensus estimate for Johnson & Johnson securities is $190-197 at the end of 2022.
On the daily chart, the MACD indicator is still declining in the negative zone and does not form a buy signal. The Stochastic oscillator is declining, approaching the oversold zone, after which it will be able to turn up and begin forming a buy signal. The technical picture does not yet give a clear signal for acquisitions, it is worth waiting for a more successful situation.
Most of the Russians have heard about Dubai, but very few are aware of Bahrai...
The USA has reached the limits of the national debt The official limit of the...
The legacy of the pandemic: remote working, isolation and skepticism 2023 wil...